系統生物學：顛覆性技術

系統生物學：顛覆性技術 是由出版商Insight Pharma Reports在2008年05月所出版的。 這份英文市場調查報告書包含156 pages 價格從美金1498起跳。

簡介

目錄

This report focuses on the current and future applications of Systems Biology in drug discovery, specifically in pinpointing optimal individual targets, and combinations of targets, to overcome metabolic pathway redundancies, leading to efficacious and safe products.

• Application successes at AstraZeneca, Pfizer, and J&J
• Landscape of the Systems Biology marketplace and its future
• Implications of innovative predictive modeling and global transcription epigenetics analysis
• Review of 18 Systems Biology company business models
• How SB will enable pharmacological progress in biologically complex "money" diseases
• Projections on the future for Systems Biology in leukemia, Alzheimer' s, and Huntington' s diseases.

Systems biology (SB) is challenging the existing dominant drug discovery approaches and on track to becoming a classic disruptive technology. This report describes examples of SB successes in big pharma and current SB applications as well as the radically new concepts emerging from basic SB research.

The report provides a survey on the origins of SB and the varying definitions in common use and then moves to a review of the current bioanalytical- and bioinformatics-based technologies for making sense of omic' s data through enabling pathway and network analysis. Pathway analysis, cell modeling, and disease modeling technologies today dominate the bioinformatics branch of systems biology. Database-mediated pathway analysis studies, which are particularly popular today, help to discover meaning in global biological data for drug discovery and diagnostics. As examples, systems biology approaches played a key role in understanding AstraZeneca' s Iressa (gefitinib), liver abnormalities were identified by Pfizer, and Johnson & Johnson identified a kinase inhibitor mechanism. Next, the report provides an overview of the recent explosion of academic SB activity and implications for highly novel approaches to drug discovery and diagnostics not envisioned today. Examples include nanosystems studies to construct a predictive model for transcription control, ChIP-on-chip technology for global transcription factor identification, and methylation-specific polymerase chain reaction (PCR) for global DNA methylation detection as an entry point to epigenetics.

Systems Biology: A Disruptive Technology provides an analysis of the commercial activities of 18 small systems biology companies reviewed in the context of the nature and dynamics of the systems biology market: the business models, deals, scope, and prospects. As examples, commercial databases and software programs from companies such as Ingenuity Systems (Redwood City, CA), GeneGo (St. Joseph, MI), and Ariadne Genomics (Rockville, MD) provide enhanced usability and comprehensiveness. Gen-struct' s Knowledge Assembly platform enables "knowledge-driven systems biology;" Gene Network Sciences' (Cambridge, MA) REFS (Reverse Engineering and Forward Simulation) systems permit reverse engineering and hypothesis generation from omic data; and Entelos' (Foster City, CA) PhysioLab biosimulation models, which incorporate both molecular and higher-order disease data, permit construction of "virtual patients."

Systems Biology: A Disruptive Technology concludes with a discussion and speculation as to the future for SB, supported by interviews with scientists and managers deeply engaged in this space. This analysis explains how and why pharma and diagnostics industries will benefit from advances in SB by leading to highly novel approaches for application to drug discovery and diagnostics discovery and development.

Table of Contents

• INTRODUCTION
• 1.1. Scope and Content of This Report
• 1.2. Historical Perspective
• 1.3. Defining Systems Biology

• TECHNOLOGICAL ASPECTS OF SYSTEMS BIOLOGY
• 2.1. Bioanalytical Technologies
  • Academic Perspective: Institute for Systems Biology
  • Commercial Perspective: BG Medicine
• 2.2. Regulatory Mechanisms and Organization
  • DNA-Protein Binding: ChIP-on-Chip Analysis
  • DNA Methylation
  • MicroRNAs
• 2.3. Bioinformatics Technologies
  • Pathway Analysis
    • Databases
    • Commercial Software Systems
  • Cell and Disease Modeling
    • Genstruct
    • Entelos
    • Gene Network Sciences
• 2.4. Summary

• BASIC RESEARCH IN SYSTEMS BIOLOGY
• 3.1. Network-Based Models and Simulations
  • Types of Biological Networks
  • Transcriptomic/Genetic Variation Approach
  • Combination Drug Therapy
• 3.2. Protein Networks
  • Yeast Two-Hybrid and Related Technologies
  • Metabolic Interaction Networks
  • Databases
  • Systems Biology Research Approaches
• 3.3. An Emerging Paradigm for Viewing Health and Disease
  • Diseaseome
  • Genotyping/Gene Expression Combinations in Biological Network Construction
  • Implications of Systems Biology for Clinical Medicine
  • Systems Biology Approach for Cancer Research

• APPLIED RESEARCH IN SYSTEMS BIOLOGY
• 4.1. Impacts of Systems Biology on Specific Disease Areas
  • Cancer
    • Acceptance of Systems Biology by Big Pharma
    • Network-Based Cancer Research
  • Neurological Diseases
  • Cardiovascular Diseases
  • Metabolic Disorders

• MARKET DYNAMICS
• 5.1. Approaches of Small-Company Players X
  • Ariadne Genomics
  • BG Medicine
  • BioSeek
  • Connexios
  • Entelos
  • Gene Network Sciences
  • GeneGo
  • Genetics Squared
  • Genomatica
  • Genstruct
  • Ingenuity Systems
  • Optimata
  • Physiomics
  • Protein Lounge
• 5.2. Approaches of Selected Drug Discovery and Development Organizations
  • Cellicon Biotechnologies
  • CombinatoRx
  • e-Therapeutics
  • Merck
  • Merrimack Pharmaceuticals
  • Pfizer
  • SU Biomedicine
• 5.3. Systems Biology Deals
• 5.4. Insight Pharma Reports Systems Biology Survey: Results and Comments

• CONCLUSIONS AND FUTURE PROSPECTS
• 6.1. Challenges for Systems Biology in Drug Discovery
• 6.2. Possible Solutions to Advancing Medical and Pharmacological Knowledge via Systems Biology
• 6.3. Systems Biology as a Disruptive Technology
• 6.4. Future Prospects

• EXPERT INTERVIEWS
• David de Graaf, PhD
• Director of Systems Biology, Pfizer, Research Technology Center, Cambridge, MA

• Brian Edmonds, PhD
• Research Advisor, Integrative Biology and Global External Research, Lilly Research Laboratories, Indianapolis, IN

• Colin Hill
• CEO, President, Chairman, and Co-Founder, Gene Network Sciences, Cambridge, MA

• David Lester, PhD
• President and Founder, ITHW, Inc., Morristown, NJ

• Stephen Naylor, PhD
• Chairman, CEO, and Co-Founder, Predictive Physiology and Medicine (PPM), Bloomington, IN

References

Company Index with Web Addresses

相關商品

以基因為基之藥物開發相關市場調查報告書

分子診斷﹕技術˙市場˙企業
Molecular Diagnostics - Technologies, Markets and Companies
價格 : US $ 5500
出版日期 : 2012年01月

蛋白質體﹕技術˙市場˙企業
Proteomics - Technologies, Markets and Companies
價格 : US $ 5000
出版日期 : 2012年01月

RNAi（RNA干擾）：技術、市場、企業
RNAi - technologies, markets and companies
價格 : US $ 4000
出版日期 : 2012年01月

Insight Pharma Reports發行的生物科技相關市場調查報告書

高含量分析:技術·用途·市場動態

High-Content Analysis: Technologies, Applications, and Market Dynamics

價格 : US $ 2495

出版日期 : 2011年12月

細胞因子治療及抑製劑：研發產品線、市場、策略性挑戰 - 概要

Cytokine-Based Therapies and Inhibitors: R&D Pipelines, Markets, and Strategic Issues - Overview

價格 : US $ 2495

出版日期 : 2011年09月

激酶標靶治療：開發產品線、挑戰及機會

Kinase-Targeted Therapeutics: Development Pipelines, Challenges, and Opportunities

價格 : US $ 3195

出版日期 : 2011年08月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!